Eli Lilly Expands Horizons: Launching Weight-Loss Drug in Emerging Markets

Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 to meet rising global demand. The strategic expansion offers a significant market opportunity due to the high prevalence of obesity in these populous countries.

Eli Lilly is forging ahead with plans to launch its leading weight-loss medication in emerging markets such as India, Brazil, and Mexico by the latter half of 2025, according to its finance chief. This move comes as the company scales up production to meet surging global demand.

The company's decision to target these countries represents a substantial market opportunity, given their large populations burdened with increasing obesity rates. This expansion positions Lilly to further capitalize on the growing need for effective weight management solutions worldwide.

The initiative to introduce the drug in these key markets could also solidify Lilly's stance in the competitive landscape against Danish rival Novo Nordisk, as both companies vie for a leading position in the diabetes and weight-loss segments.

(With inputs from agencies.)